GlassScriptPhysician profile
Robert L Donald
NPI 1770585630
$8,925.29
in general payments reported to CMS, 2019-2025
37 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,070 · 2020: $968 · 2021: $1,311 · 2022: $1,550 · 2023: $1,801 · 2024: $1,179 · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,985 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,985.15 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,638.61 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,423.46 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,111.17 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $588.43 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $536.65 | 2022-2024 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $529.56 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $445.34 | 2021-2025 | Freestyle Libre |
| Pfizer INC. | $316.60 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $306.43 | 2022-2025 | |
| Amgen INC. | $268.59 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Renalytix Ai, INC. | $202.05 | 2023-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $180.60 | 2022 | |
| Amarin Pharma, INC. | $162.58 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $158.57 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $135.32 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $105.53 | 2019-2025 | Veozah, Myrbetriq |
| Grt US Holding, INC. | $87.16 | 2022 | |
| Merck Sharp & Dohme LLC | $86.73 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $73.22 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $71.10 | 2020-2023 | Livalo, Seglentis |
| Exact Sciences Corporation | $59.60 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $56.96 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.41 | 2021 | |
| Radius Health, INC. | $37.88 | 2019 | |
| Biogen, INC. | $31.83 | 2020-2021 | |
| Sanofi Pasteur INC. | $31.00 | 2019 | |
| Corcept Therapeutics | $30.12 | 2021-2023 | Korlym |
| Avanir Pharmaceuticals, INC. | $29.55 | 2019-2022 | |
| Averitas Pharma INC. | $29.29 | 2025 | Qutenza |
| Allergan, INC. | $24.78 | 2019-2020 | |
| Dexcom, INC. | $17.85 | 2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $17.52 | 2023 | Rexulti |
| Esperion Therapeutics, INC. | $17.45 | 2020 | |
| Daiichi Sankyo INC. | $17.23 | 2019 | |
| Medtronic, INC. | $16.32 | 2025 | Inceptiv |
| Gilead Sciences, INC. | $13.46 | 2021 | |
| Genentech USA, INC. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Donald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.